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Abstract
With the increasingly widespread use of antipsychotics in bipolar disorder (BD), switching among these agents
and between antipsychotics and mood stabilizers has become more common, in particular, since the introduction
of the novel atypical antipsychotics with mood stabilizer properties. This systematic review aims to provide a
comprehensive update of the current literature in BD about the switching of antipsychotics, among them and
between them and mood stabilizers, in acute and maintenance treatment. We conducted a comprehensive, com-
puterized literature search using terms related to antipsychotic switching in BD in the PubMed/Medline,
PsycINFO, CINAHL database; the Cochrane Library and; the Clinicaltrials.gov web up to January 9th, 2013
according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.
The search returned 4160 articles. After excluding duplications, reviews, case reports and studies that did not
fulﬁl the selection criteria, 8 studies were included. Not only have few articles on antipsychotic switching
been published but also recruitment in most studies included mixed samples of patients. In general, antipsycho-
tic switching, regardless of the route of drug administration, was well tolerated and no interference was shown in
antipsychotic effectiveness during the interchange of drugs. Metabolic improvement was perceived when the
switch involved antipsychotics with a low metabolic risk proﬁle. The evidence-base for antipsychotic switching
in BD is scant, and little controlled data is available. Switch from quetiapine to lithium and from risperidone to
olanzapine has proven successful. Switching to antipsychotics with low metabolic risk had some positive impact
on several safety measures. In stabilized patients, the plateau cross-taper switch may be preferred.
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Introduction
Pharmacological strategies in bipolar disorder (BD) have
widely broadened in the last few years due, to some
extent, to the introduction of atypical antipsychotics in
therapeutic options (Yatham et al., 2009; Liauw and
McIntyre, 2010; Vieta et al., 2013). Currently, not only is
there abundant evidence suggesting the efﬁcacy of anti-
psychotics in acute mania, particularly for their fast
onset effect (Nivoli et al., 2011b, 2013; Yildiz et al., 2011;
Goikolea et al., 2013; Vieta and Valentí, 2013a), but anti-
psychotics are also a well-grounded treatment for acute
depression and the prevention of relapses (Cruz et al.,
2010; Frye et al., 2011; Nivoli et al., 2011a; Vieta et al.,
2011; Grunze et al., 2013; Vieta and Valentí, 2013b).
Achieving an adequate pharmacological strategy in
BD, as well as in other psychiatric disorders, occasionally
implies changes among the different therapeutic alterna-
tives (Fountoulakis et al., 2012; Grande et al., 2013). The
reasons for switching may be diverse and involve: the
particularities of individual patients with their own
beliefs, expectations, adherence, brain biology and thera-
peutic alliance (Haro et al., 2011); the illness itself (Grande
et al., 2012); the medication and its pharmacodynamics
(Reinares et al., 2012); and, the environment (Buckley
and Correll, 2008).
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Knowledge about the strategies for dosing and
switching of antipsychotics has been growing, based, in
particular, on the literature on schizophrenia and
schizoaffective disorder (Bernardo et al., 2011; Correll,
2011; Murru et al., 2011b; Stahl, 2013). In the ﬁeld of
BD, there is still a scarcity of evidence about this issue
and, indeed, no speciﬁc clinical guidelines for the safe
and effective interchange of these dissimilar drugs have
been addressed. Only some indirect data and case reports
have been published in this regard (Gardner et al., 1997;
Rachid et al., 2004; Koener et al., 2007; Yang and Liang,
2011).
Careful antipsychotic dosing and judicious changes
using appropriate switching strategies (Fig. 1) may help
clinicians reduce discontinuation rates and unnecessary
pharmacological modiﬁcations in BD (Buckley and
Correll, 2008). This systematic review aims to provide a
comprehensive update of the current literature in BD
about the switching of antipsychotics, among them and
between them and mood stabilizers, in acute and main-
tenance treatment. This information may be of special
interest to clinicians, so as to determine adequate
approaches for the optimal clinical management of
patients with bipolar disorder.
Method
Data for this systematic review were collected with an
advanced document protocol in accordance with the
PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines (Moher et al.,
2009; Urrútia and Bonﬁll, 2010). This proposal provides
guidance for optimal reporting of systematic review
protocols.
Data sources
A comprehensive, computerized literature search was
conducted in the PubMed/Medline, PsycINFO, CINAHL
database; the Cochrane Library and, the Clinicaltrials.
gov web without language restrictions and up to
January 9th, 2013. Our phrase and Boolean logic algo-
rithms were [‘bipolar disorder’ AND (switch OR switching
OR change OR substitution OR shift) AND (antipsychotic
OR antipsychotics OR aripiprazole OR asenapine OR chlor-
promazine OR clozapine OR ﬂuphenazine OR haloperidol
OR olanzapine OR perphenazine OR quetiapine OR risperi-
done OR thioridazine OR ziprasidone)] as well as [‘bipolar
disorder’ AND (switch OR switching OR change OR substi-
tution OR shift) AND (antipsychotic OR antipsychotics OR
aripiprazole OR asenapine OR chlorpromazine OR clozapine
OR ﬂuphenazine OR haloperidol OR olanzapine OR perphena-
zine OR quetiapine OR risperidone OR thioridazine OR zipra-
sidone) AND (lithium OR ‘valproic acid’ OR carbamazepine
OR oxcarbazepine)]. Using the PRISMA statement, articles
were selected based on title and abstract and, when
necessary, on examination of the full text to assess rel-
evance. Records retrieved through references of relevant
articles, conference abstracts or registered clinical trials
were screened for additional reports not previously iden-
tiﬁed. We also contacted authors to obtain information
about studies. The ﬁrst and last author of this study inde-
pendently carried out the search. Any inconsistency was
discussed and resolved. A search for published articles
written by speciﬁc authors who had been working on
clinical trials about atypical antipsychotics was also car-
ried out.
Study selection
Records were reviewed using the following inclusion
criteria: (1) original published longitudinal study report-
ing full results, (2) detailed description of the switching
method and methodological background that evaluated
BD using validated instruments or a semi-structured in-
terview performed by a trained clinician based on DSM-
IV-TR criteria, and (3) sample size >10 subjects diagnosed
with BD. The following exclusion criteria were applied:
(1) reports not published, (2) uncompleted studies, (3) case
reports, (4) reviews, and (5) abstract with no results.
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Fig. 1. Antipsychotic switching strategies (a) abrupt discontinuation of the current antipsychotic and immediate implementation of
the new antipsychotic; (b) gradual cross-tapering of the current antipsychotic and the new antipsychotic; (c) continuation of the ﬁrst
antipsychotic at full dose while gradually tapering the new antipsychotic up to the optimal dose. When optimal dose is reached,
proceed to the discontinuation of the ﬁrst drug.
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Results
Using the aforementioned keywords, the search returned
4160 records whose title and abstracts were examined
(Fig. 2). We excluded 4139 articles because they were
duplicated records and did not meet a priori the selection
criteria. One article was obtained by speciﬁc expert
author search. We further identiﬁed 36 potentially rel-
evant articles through cross-referenced bibliographies,
which were thoroughly examined. Thirty-six did not
fulﬁl inclusion criteria. We detected 8 out of 60 clinical
trials apparently meeting the inclusion criteria. The
NCT00246246 presented already published results,
which were obtained by means of other databases
(Yatham et al., 2007). In 4 completed clinical trials, the
results were not available. Of the remaining 3 trials,
2 were ongoing and, in the other 1, the recruitment status
was unknown. Twenty-ﬁve full text articles (Gardner
et al., 1997; Bogan et al., 2000; Kluznik et al., 2001; Pae
et al., 2004; Rachid et al., 2004; Brown et al., 2005; Savas
et al., 2006; Buckley, 2007; Hilwerling et al., 2007;
Koener et al., 2007; Spurling et al., 2007; Yatham et al.,
2007; Buckley and Correll, 2008; El-Mallakh et al., 2008;
Wilting et al., 2008; Chandrasena et al., 2009; Bobo
et al., 2010; Liauw and McIntyre, 2010; Bernardo et al.,
2011; Correll, 2011; Di Sciascio et al., 2011; Weisler
et al., 2011; Yang and Liang, 2011; Chen et al., 2012;
Vieta et al., 2012) were assessed for eligibility and in the
end, 8 full text articles were included in the systematic re-
view (Fig. 2) (Pae et al., 2004; Brown et al., 2005; Savas
et al., 2006; Yatham et al., 2007; El-Mallakh et al., 2008;
Weisler et al., 2011; Chen et al., 2012; Vieta et al., 2012).
The characteristics of the articles selected are reported in
Table 1.
Switching antipsychotics
Unlike other psychiatric disorders such as schizophrenia
or schizoaffective disorder, scant literature is available in
the ﬁeld of BD concerning the switching of antipsychotics.
4160 records indentified through
database searching
-Pubmed/Medline : 1756 
-PsyclNFO: 862
-ClinicaITrials: 656
-Cochrane: (ENG: 251, SPA: 541)
-CINAHL: 9I
de
nt
ifi
ca
tio
n
S
cr
ee
ni
ng
El
ig
ib
ili
ty
In
cl
ud
ed
1 additional record identified
through other sources
-Manual search: 1
2957 duplicated records:
-Pubmed/Medline : 1155
-PsycINFO: 534
-ClinicaI Trials: 596
-Cochrane: (ENG: 132, SPA: 496)
-CINAHL: 44
1182 studies excluded by title or abstract
1204 records after duplicates removed
22 full text articles assessed for eligibility 
14 full text articles excluded, due to: 
- 3 study design (a)
- 2 inclusion criteria (b)
- 3 case reports (c)
- 6 reviews (d)
8 studies included (e)
Fig. 2. PRISMA ﬂow-chart of the studies considered and ﬁnally selected for review (Moher et al., 2009; Urrútia and Bonﬁll, 2010).
(a) (Kluznik et al., 2001; Spurling et al., 2007; Wilting et al., 2008; Chandrasena et al., 2009; Di Sciascio et al., 2011). (b) (Bogan et al.,
2000; Hilwerling et al., 2007). (c) (Rachid et al., 2004; Koener et al., 2007; Yang and Liang, 2011). (d) (Buckley, 2007; Buckley and
Correll, 2008; Bobo et al., 2010; Liauw and McIntyre, 2010; Bernardo et al., 2011; Correll, 2011). (e) (Kluznik et al., 2001; Pae et al.,
2004; Brown et al., 2005; Yatham et al., 2007; El-Mallakh et al., 2008; Weisler et al., 2011; Chen et al., 2012; Vieta et al., 2012).
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Table 1. Characteristics of the studies selected about switching antipsychotics and switching between mood stabilizers and antipsychotics
Study Sample Design
Duration
(wk) Outcome measures Results summary Comments
Switching antipsychotics
Acute treatment
(Pae et al., 2004) 18 manic BD-I
inpatients intolerant to
ris in combined
treatment with mood
stabilizer and ris
Open-label study with
non-tapered switch from ris to
quetiapine as add-on mood
stabilizer treatment
3 Efﬁcacy: CGI, YMRS Safety:
BARS, SAS, DAI-10
Quetiapine was an effective
and tolerated switching
option for patients intolerant
to ris with acute mania.
Prospective
non-comparative study.
Maintenance treatment
(Chen et al., 2012) 27 BD-I patients who
evidenced adverse
metabolic side effects
(TG/HDL53.5) (out of
52 patients)
Randomized, open-label
study with cross-taper switch
from A to aripiprazole (n=11)
or ziprasidone (n=16)
52 Effectiveness: YMRS, HDRS,
QLS, GAF Safety: weight,
BMI, total cholesterol, HDL,
LDL, TG, HbA1c, BARS, SAS,
AIMS
Signiﬁcant improvement in
metabolic proﬁle
(ziprasidone: more
favourable in total cholesterol
and HDL values;
aripiprazole: more favourable
in TG/HDL ratio and HbA1c
values)
Results were obtained in the
whole sample of patients
diagnosed with BD, SCH or
SAD. No independent effect
of diagnosis was found.
(Yatham et al., 2007) 49 BD I/II outpatients
under combined
treatment of mood
stabilizer and OAA
Randomized, open-label trial
with cross-switch from OAA
(n=26) to LAI-ris (n=23) as an
add-on mood stabilizer
treatment
26 Effectiveness: number of
interventions, CGI, YMRS,
MADRS, HARS, EuroQol-5D,
satisfaction VAS, time to
intervention Safety: report of
adverse events, laboratory
test, vital signs, weight,
BARS, SAS, AIMS
No signiﬁcant differences in
effectiveness, safety,
tolerability or adverse events
between groups LAI-ris
showed signiﬁcant reduction
in means CGI and YMRS at
follow-up, while OAA had
signiﬁcant reduction in
HARS.
Not double-blind design.
Small sample size.
(Savas et al., 2006) 12 noncompliant BD-I
patients
Open-label study with
cross-taper switch from OAA
to ﬁrst LAI (ris) as unique
treatment or add-on mood
stabilizer
26 Efﬁcacy: BRMAS, HDRS, CGI Signiﬁcant improvement
(achieving remission in all
patients)
Only patients that showed
full adherence to LAI-ris
over 6 mth were included in
the study.
(Vieta et al., 2012) 131 BD-I patients Randomized, double-blind,
placebo-controlled trial with
cross switch arm from LAI-ris
to olanzapine
78 Efﬁcacy: Primary outcome:
time to recurrence of any
mood episode; Others: YMRS,
MADRS, CGI Safety: weight
gain, vital signs, ESRS
Time to recurrence of any
mood episode was
signiﬁcantly longer with oral
olanzapine compared to
LAI-ris, especially for
depressive mood episodes
Exploratory analyses
Enriched study (LAI–ris
responder-rich population)
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(Brown et al., 2005) 19 BD-I/II patients on
current substance
abuse (out of 20)
Retrospective open-label
study with cross-taper switch
from A to aripiprazole
12 Efﬁcacy: YMRS, HDRS, BPRS,
substance craving VAS,
dollars spent, substance use
Safety: BARS, SAS, AIMS
Signiﬁcant clinical
improvement without
changes in tolerability
Alcohol dependence:
reduction in money spent on
alcohol and alcohol craving
Cocaine: reduction in craving
1 of the 20 patients was
diagnosed with SAD
bipolar type. High attrition
(13/20). Small sample.
Switching between mood stabilizers and antipsychotics
Acute treatment
(El-Mallakh et al., 2008) 38 BD-I patients
non-responders to
olanzapine in manic or
mixed episode (out
of 155)
Randomized,
placebo-controlled trial with
switch arm from olanzapine
to carbamazepine
extended-release capsules
after washout of 2–5 days
3 Efﬁcacy: Primary outcome:
YMRS; Secondary outcome:
HDRS, CGI
Clinical signiﬁcance
improvement almost
achieved
Exploratory analyses.
Underpowered analysis.
Maintenance treatment
(Weisler et al., 2011) 176 quetiapine
stabilized BD-I patients
who had an affective
event
Randomized, double-blind,
placebo-controlled trial with
switch arm from quetiapine to
lithium
104 Effectiveness: Primary
outcome: time to recurrence
of any mood event;
Secondary outcome: time to
recurrence of a manic,
depressive event, MADRS,
YMRS, CGI, PANSS-P, SDS
Safety: weight, BMI, SAS,
BARS, AIMS, vital signs,
physical, laboratory and ECG
assessment
In patients stabilized during
acute quetiapine treatment,
continuation on this
treatment signiﬁcantly
increased time to recurrence
of any mood, especially
depressive events compared
to lithium. Overall rates of
adverse events were
generally similar between
treatment groups
Enriched design resulting in
a selection bias in favour of
quetiapine
A: antipsychotics, AIMS: abnormal involuntary movements scale, BARS: Barnes akathisia rating scale, BD: bipolar disorder, BMI: body mass index, BPRS: brief psychiatric rating scale, BRMAS:
Bech-Rafaelsen mania rating scale, CGI: clinical global impression-bipolar scale, DAI-10: drug attitude inventory shortened version-10, ECG: electrocardiography, ESRS: extrapyramidal symptoms
rating scale, GAF: global assessment of functioning score, HARS: Hamilton anxiety rating scale, HbA1c: glycosylated hemoglobin, HDL: high density lipoprotein, HDRS: Hamilton depression
rating scale, LAI: long acting injection, LAI-ris: risperidone long acting injection LDL: low-density lipoprotein, MADRS: Montgomery-Asberg depression rating scale, OAA: oral atypical antipsy-
chotics, PANSS-P: positive and negative syndrome scale-positive symptom subscale, QLS: quality of life scale, ris: risperidone, SAD: schizoaffective disorder, SAS: Simpson-Angus scale, SCH:
schizophrenia, SDS: Sheehan disability scale, TG: triglycerides, VAS: visual analog scale, YMRS: Young mania rating scale.
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Not only have few articles on this topic been written but
also the recruitment in most includes mixed samples of
patients with BD, schizophrenia or other related psy-
chotic disorders. The bibliography around this topic is
principally focused on the comparison of the efﬁcacy, ef-
fectiveness and safety among antipsychotics since they
are the main reasons that lead to antipsychotic switching.
These aspects have been assessed in acute and mainten-
ance treatment, mainly considering the new atypical anti-
psychotics with oral and long-acting injectable (LAI)
administration.
Acute treatment
Regarding treatment in acute mania, we found 1 article in
which quetiapine was assessed as an add-on treatment in
inpatients under mood stabilizer treatment and having
displayed intolerance to risperidone (Pae et al., 2004).
Intolerance was deﬁned as the patients’ subjective com-
plaint and clinicians’ observation of akathisia and dysto-
nia assessed by the Barnes Akathisia Rating Scale (BARS)
and the Simpson-Angus Rating Scale (SARS). Eighteen
patients completed this 3-wk trial. The Young Mania
Rating Scale (YMRS) and Clinical Global Impression
(CGI) scale scores signiﬁcantly decreased from the time
of admission to the end-point regardless of the mood
stabilizer used. The SARS and BARS scores at baseline
were signiﬁcantly higher than at admission, showing an
increase during the treatment with risperidone. The
mean Drug Attitude Inventory short version-10 (DAI-10)
score at baseline was signiﬁcantly inferior compared
with that upon admission. The SARS and BARS scores
improved signiﬁcantly at the end-point compared with
baseline, with a mean change of 75% (1.8±0.9, p<0.0001)
and 77.8% (1.4±0.8, p<0.001), respectively. The DAI-10
scores also changed to a positive response with statistical
signiﬁcance from baseline to the end-point (−1.7±0.7 vs.
0.8±0.9, p<0.001). On subgroup analyses according to
the mood stabilizer, lithium and valproate did not show
any signiﬁcant differences in tolerability. Moreover, the
use of benztropine, an anticholinergic drug for extrapyra-
midal side effects, signiﬁcantly decreased from baseline to
the end-point. While an improvement in extrapyramidal
symptoms was depicted, other side effects such as sed-
ation and gastrointestinal irritation were presented in
more than half of the sample during the treatment with
quetiapine. Moreover, one patient discontinued the trial
due to excessive somnolence. The mean weight of the sub-
jects increased signiﬁcantly from baseline to the end-point
(2.4±1.2 kg, p<0.001).
Maintenance treatment
Considering the side effects that may occur in long-term
treatment, the metabolic and cardiovascular proﬁles of
antipsychotics are of concern among patients and physi-
cians, in particular, those drugs with a high histaminergic
afﬁnity such as clozapine and olanzapine (Buckley, 2007;
De Hert et al., 2012). In fact, investigations on the meta-
bolic proﬁle of antipsychotics and treatment for the re-
lated side effects are currently ongoing. The risk of
adverse metabolic effects varies considerably among anti-
psychotic drugs, aripiprazole and ziprasidone seeming to
have a better metabolic proﬁle (De Hert et al., 2012).
Chen et al. (2012) compared the metabolic proﬁle and
effectiveness of antipsychotic switching to aripiprazole
or ziprasidone in a 52-wk follow-up. In this clinical
trial, a mixed sample of patients diagnosed with BD,
schizophrenia and schizoaffective disorder presenting ad-
verse metabolic side effects were recruited. An adverse
metabolic side effect was deﬁned as a triglyceride/high-
density lipoprotein (TG/HDL) ratio 53.5. The most
prevalent antipsychotic treatments were quetiapine,
risperidone, and olanzapine. Patients were randomly
assigned to treatment with aripiprazole or ziprasidone:
11 out of 24 patients with BD received aripiprazole at
5–30mg/d and 16 out of 28 received ziprasidone at
40–160mg/d. The new antipsychotic was titrated to reach
target dose within 2 wk, according to the clinical effect
(at the physicians’ discretion) while the previous antipsy-
chotic was progressively withdrawn. During the follow-
up, signiﬁcant improvements in body weight, body mass
index, triglycerides (TG), high-density lipoprotein (HDL)
levels and the TG/HDL ratio were registered. There were
no differences between the 2 treatments during the moni-
toring except in body weight and glycated haemoglobin
A1c (HbA1c), in which a greater reduction was detected
in the ziprasidone and the aripiprazole groups, respect-
ively. Following the switch to ziprasidone, an earlier re-
duction in body weight was observed compared to the
aripiprazole group. The least square mean decrease in
body weight at 52 wk was −13.97 (3.14) pounds for zipra-
sidone and−1.47 (3.57) pounds for aripiprazole (p=0.004).
A sensitivity analysis, that excluded patients who received
concomitant valproic acid and those who took therapy
with antihyperlipidaemic and antidiabetic agents, sup-
ported the primary analysis for all lipid measures.
RegardingHbA1c, it is of note that the effect on the glycae-
mic proﬁle remained signiﬁcant after excluding subjects
who received concomitant valproic acid, butwas no longer
signiﬁcant after excluding patients who initiated antidia-
betic or antihyperlipidemic treatment. Although having
recruited a mixed sample, no independent effect of the
diagnostic group on anthropometric or metabolic mea-
sures over timewasdetected.Moreover, the change of anti-
psychotic did not interferewith the stability of the patients,
showing no signiﬁcant time or group per time interaction
effects for most psychopathological measures except
Global Assessment of Functioning scores that improved
more in the aripiprazole group compared to the ziprasi-
done group.
Regarding the route of antipsychotic administration,
studies on tolerability and effectiveness have also been
carried out. Yatham et al. (2007) studied the oral and
LAI administration of atypical antipsychotics (AA) as an
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add-on maintenance mood stabilizer treatment over
6 mth. Patients were maintained on the previous mood
stabilizer and were randomized to current AA or to
LAI-risperidone (LAI-ris). Patients on LAI-ris treatment
received a 25mg injection every 2 wk for at least 6 wk
with an initial 3 wk oral supplementation over their
current oral AA. Of a sample of 49 subjects, 26 were
randomized to oral AA, in particular quetiapine and
olanzapine, and 23 to LAI-ris. No signiﬁcant differences
between treatment with LAI-ris or oral AA were found
in either effectiveness or safety except that the LAI-ris
group presented signiﬁcant reductions in symptoms by
means of the CGI and the YMRS scores while the oral
AA group had signiﬁcant reductions in the Hamilton
Anxiety Rating Scale scores. Although 71% of the patients
in the study reported at least 1 adverse event, only
3 subjects under LAI-ris and none under oral AA
dropped out due to adverse events. A total of 5 patients
in each group had an intervention for mood symptoms.
In a retrospective study in non-compliant bipolar
patients, Savas et al. (2006) also evaluated the efﬁcacy
of LAI-ris as the ﬁrst LAI antipsychotic compared to
other oral antipsychotic treatments. The previous oral
antipsychotic was continued for 3 wk after the ﬁrst injec-
tion of LAI-ris. Signiﬁcant improvement was shown at
the ﬁrst month assessment and was maintained during
the 6-mth follow-up. In fact, all the patients met criteria
for remission. No patient had any manic or depressive re-
lapse during the 6-mth treatment with LAI-ris compared
with 1.42 mean episodes that occurred during the 6 mth
prior to the antipsychotic switch.
Recently, Vieta et al. (2012) studied the efﬁcacy and
safety of LAI-ris for preventing recurrence of mood epi-
sodes in patients with BD-I in an international 18-mth
randomized, double-blind trial. Patients who had not pre-
viously experienced recurrence during a 12-wk open-
label trial with LAI-ris were included. Subjects were to
discontinue treatment of all antipsychotics or mood stabi-
lizers during this period. The patients were randomized
to 3 treatment arms: (a) LAI-ris with variable doses
from 25, 37.5 to 50mg plus oral placebo (n=132);
(b) oral and injectable placebo (n=135), and (c) injectable
placebo with oral olanzapine (10mg/d) (n=131) as a posi-
tive comparator. The primary efﬁcacy end-point was time
to recurrence of any mood episode for LAI-ris vs. placebo.
This is the only controlled trial so far to show a signiﬁcant
advantage for a switching strategy over staying on the
same drug after stabilization; hence, olanzapine was sign-
iﬁcantly more effective not only than placebo but also
than long-acting injectable risperidone, despite the fact
that all patients had been stabilized with risperidone.
Importantly, the producer of risperidone, not olanzapine,
sponsored the trial. The time to ﬁrst recurrence of any
mood episode, which was the primary outcome, did not
show signiﬁcant differences between LAI-ris and placebo,
but there was a trend (p=0.056). Only time to an elevated
mood episode was signiﬁcantly longer in the LAI-ris arm
compared with the placebo arm, with no signiﬁcant dif-
ferences in the depressive recurrences. The time to recur-
rence of any mood episode as well as an elevated mood
episode or depressive episode was signiﬁcantly longer
with oral olanzapine than with placebo. An additional ex-
ploratory analysis showed that the time to recurrence of
any mood episode was also signiﬁcantly longer with
oral olanzapine compared to LAI-ris (p=0.001, stratiﬁed
by region) and that the time to recurrence of an elevated
mood episode (p=0.054, stratiﬁed by region) or depress-
ive mood episode (p=0.004, stratiﬁed by region) was
longer with oral olanzapine compared to LAI-ris, es-
pecially for depressive mood episodes. Focusing on toler-
ability, the most common adverse events occurring in
patients receiving LAI-ris were weight increase, insomnia
and amenorrhea, weight increase, somnolence and in-
somnia in the olanzapine arm. Due to adverse events,
5 patients in both the LAI-ris and olanzapine arms, dis-
continued the study while 2 patients abandoned the pla-
cebo group.
The practicability of an antipsychotic switch has also
been evaluated in patients with BD and co morbid sub-
stance abuse disorders. Brown et al. (2005) studied the
switch to aripiprazole from an atypical antipsychotic in
19 outpatients with BD and 1 with schizoaffective dis-
order, bipolar type. Most patients received quetiapine,
olanzapine and risperidone. The change consisted in a
progressive tapering of the previous antipsychotic treat-
ment over a period of up to 6 wk, while aripiprazole
was initiated at 15mg/d and could be increased at any
follow-up appointment up to 30mg/d based on clinician
judgment. This 12-wk follow-up pilot study suggested
that patients with BD or schizoaffective disorders and
co morbid substance abuse clinically beneﬁted from the
switch, showing a reduction in substance use and crav-
ing, without a modiﬁcation in side effects. In 17 partici-
pants with current alcohol dependence, signiﬁcant
reductions in dollars spent on alcohol (p=0.042) and al-
cohol craving (p=0.003) were found. In 9 participants
with cocaine-related disorders, signiﬁcant reduction in
cocaine craving (p=0.014) was shown.
Switching between mood stabilizers and antipsychotics
As the use of antipsychotics has become more wide-
spread in BD, switching among these agents has become
more common, in particular, since the introduction of
the novel atypical antipsychotics with mood stabilizer
properties. Due to this feature, studies have been
designed to focus on the switch between mood stabilizers
such as valproate, lithium or carbamazepine, to antipsy-
chotics or vice versa in both acute and maintenance
treatment.
Acute treatment
El-Mallakh et al. (2008) assessed the efﬁcacy of
extended-release carbamazepine as treatment for mania
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or mixed episodes in patients with BD who had not pre-
viously responded to olanzapine (n=38), lithium or
valproate by means of a post-hoc analysis of pooled data
from 2, multi-centre, placebo-controlled 3-wk trials.
Carbamazepine monotherapy was introduced after a
washout period of 2–5 days. In subjects receiving
extended-release carbamazepine the clinical scores sign-
iﬁcantly improved compared to subjects receiving
placebo when they had previously taken lithium or
valproate. Signiﬁcance was not achieved if they were pre-
viously on olanzapine compared to the placebo group,
but there was a trend (p=0.06).
Maintenance treatment
The effectiveness and safety of quetiapine monotherapy
has been compared with switching to placebo or lithium
(Weisler et al., 2011). In this 104-wk double-blind
trial, patients who achieved stabilization for at least
4 wk of treatment with quetiapine were randomized to
continue quetiapine or to switch to placebo or lithium,
with lithemia ranging from 0.6 to 1.2 mEq/l. Time to re-
currence of any mood event was signiﬁcantly longer for
the group treated with quetiapine vs. placebo and for
the group treated with lithium compared to placebo.
Compared to receiving lithium, the group of patients re-
ceiving quetiapine presented with signiﬁcantly longer
times to any mood or depressive event (HR=0.66,
95%CI: 0.49–0.88, p=0.005; HR=0.54, 95%CI: 0.35–0.84,
p=0.006) suggesting that quetiapine is effective against
both poles of the illness (Popovic et al., 2012). However,
despite a signiﬁcantly shorter time to recurrence when
switched from quetiapine to lithium, patients receiving
lithium ended up with similar recurrence rates to those
staying on quetiapine, and lower recurrence rates than
those switched to placebo, proving that the switch from
quetiapine to lithium is feasible and effective.
Discussion
Despite the extensive work in the ﬁeld of antipsychotics
in BD and the expected prompt results of the ongoing
clinical trials, a formally evaluated and clearly articulated
approach of antipsychotic switching in BD is still
lacking. Psychiatrists in BD currently rely on strategies
recommended mainly for psychosis, since they are the
most evidenced-based at present (Buckley and Correll,
2008). The current review covers the evidence available
for switching among antipsychotics and between antipsy-
chotics and mood stabilizers in BD.
Careful choice of the initial medication is advisable
from the very beginning. For instance, an antipsychotic
with adverse metabolic effects in a patient with a history
of cardiovascular disease is not recommended, in spite of
the efﬁcacy of the treatment, since, in the long-term, the
treatment may have a detrimental effect on the patient
and treatment will have to be reassessed at some time.
In line with this, the weight loss or the improvement in
metabolic proﬁle obtained by switching to aripiprazole
or ziprasidone should be borne in mind (Goodwin
et al., 2011; Kemp et al., 2012). In a retrospective chart re-
view, Spurling et al. (2007) assessed the metabolic con-
sequences of antipsychotics in a mixed sample, in which
5 out of 24 were patients diagnosed with BD. Metabolic
modiﬁcations were immediately seen after the switch
to aripiprazole from another second-generation anti-
psychotic: total cholesterol signiﬁcantly decreased as
did low-density lipoprotein and weight, regardless of
whether patients were on antihyperlipidaemic treatment
or not. In the study by Chen et al. (2012), this switch
involved a weight loss of 6.4 (1.4) kg in the group of
patients who switched to ziprasidone and 0.7 (1.6) kg in
the group of patients who switched to aripiprazole.
Although metformin, sibutramine, topiramate and rebox-
etine are recommended for routine use in clinical practice,
they have demonstrated a modest, albeit statistically sign-
iﬁcant, mean short-term weight loss (Maayan et al., 2010).
We not only have to take into consideration the metabolic
effect itself of the antipsychotics but also the electro-
cardiologic consequences, such as sudden cardiac death
(Grande et al., 2011). Di Sciascio et al. (2011) evaluated
the differential effect on a potential marker of sudden
cardiac death, such as QTc enlargement, between adding
or switching antipsychotics. Despite the small sample
size, the results indicated that an antipsychotic add-on
signiﬁcantly increased the QTc interval compared to
an antipsychotic switch in patients diagnosed with BD
and schizophrenia without medical co morbidities. There-
fore, it is advisable to discern the optimal treatment and
dose before considering a switch and to avoid the use
of polypharmacy as far as possible.
When weighing up the advantages and disadvantages
of antipsychotic switching, it becomes crucial to assess
the efﬁcacy proﬁles, receptor binding afﬁnities, half-lives,
tolerability and neurocognitive impact of the antipsycho-
tics as well as the individual distinguishing features of
each patient (Buckley, 2007; Popovic et al., 2011; Torrent
et al., 2011). In the Pae et al., study (2004), the switch
strategy might have been rather far from the ordinary
clinical practice since the initial dose of quetiapine was
160.5±56.7mg, a relatively high dose compared with con-
ventional titration. Titration should be carried out until
efﬁcacy is achieved, until side effects appear or until the
maximum recommended dose is reached (Murru et al.,
2011a). In the randomized open-label clinical trial by
Yatham et al. (2007), the pharmacodynamic proﬁle of
LAI-ris and the more stringent design of prescription in
the LAI-ris group compared to the group treated with
oral atypical antipsychotic may have biased the results
in favour of the oral treatment. On the contrary, the i.m.
administration route of an antipsychotic can improve
the clinical outcome enhancing adherence, such as in
the study carried out by Medori et al. (2005). Despite
the presupposed bioequivalence of brand drugs and
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generic drugs, studies about this topic have also been car-
ried out. Kluznik et al. (2001) compared the efﬁcacy of
Clozaril® with the generic clozapine in a mixed sample
in which patients diagnosed with BD were also recruited.
In general, patients worsened on the switch from the
brand name drug to generic clozapine, similar to what
was described in a series of case reports in which the
switch from clozapine to risperidone was assessed
(Gardner et al., 1997).
The heterogeneity of the articles obtained in this
systematic review from a methodological point of view
should be taken into account (Colom and Vieta, 2011).
The randomized controlled trials by Weisler et al. (2011)
and Vieta et al. (2012) have an enriched design. In the
Weisler study, a selection bias could have favoured the
non-switching group (quetiapine-quetiapine), because
all patients had previously responded to and tolerated
quetiapine during the pre-randomization phase. In
the Vieta trial, however, the outcome was better in the
switching group (risperidone-olanzapine). Most of the
advantage of olanzapine over risperidone was achieved
in preventing depressive episodes, despite the fact that
previous studies failed to show positive results in the pre-
vention of depressive recurrences for olanzapine (Cipriani
et al., 2010; De Fruyt et al., 2012). In another study cited,
Savas et al. excluded patients that had not shown adher-
ence to LAI-ris over 6 mth and had been diagnosed with
substance abuse co morbidities (Savas et al., 2006) and,
therefore selected the most adherent patients. In the
Brown et al. study (2005), the attrition rate may have
also contributed to the heartening results since only the
data obtained from the 7 out of 20 participants that com-
pleted the 12-wk study were considered.
Antipsychotic switching is a current hot issue in the
ﬁeld of BD due to the established evidence of the effec-
tiveness of antipsychotics in BD (Vieta et al., 2011;
Yildiz et al., 2011). Controlled, randomized, double-blind,
parallel-group trials are currently carried out to establish
effectiveness of new psychopharmacological drugs for
regulatory purposes (Vieta and Cruz, 2012). This system-
atic review identiﬁed very few studies that had the mini-
mal quality to be considered informative, but the results
indicate that switching from antipsychotics to mood sta-
bilizers, and from antipsychotics to antipsychotics can
be beneﬁcial under certain circumstances. Speciﬁcally,
quetiapine can be switched to lithium and long-acting
injectable risperidone can be switched to oral olanzapine
with little detriment, if any, of efﬁcacy; moreover, meta-
bolic safety and tolerability can be improved when
switching from olanzapine, risperidone or quetiapine to
aripiprazole or ziprasidone. As regards to the ideal strat-
egy, abrupt switching is only justiﬁed in acutely ill
patients or for emergency reasons. Plateau cross-taper is
advised in patients who achieved remission but whom re-
port tolerability issues related to the drug that helped to
achieve remission. However, the evidence-base for these
statements is rather weak. In the coming years, treatment
switching needs to be more thoroughly addressed and
investigated in studies properly designed to that effect
in the ﬁeld of bipolar disorder.
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